Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin- resistant subpopulations of Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2409-2412

  Liang, Beibei ^a   Bai, Nan ^a   Cai, Yun ^a   Wang, Rui ^a   Drlica, Karl ^b   Zhao, Xilin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; HOLLOW FIBER; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; STAPHYLOCOCCUS AUREUS;

EID: 79955546427     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00975-10     Document Type: Article

References (26)

1. Ambrose, P., A. Zoe-Powers, R. Russo, D. Jones, and R. Owens. 2002. Utilizing pharmacodynamics and pharmacoeconomics in clinical and formulary decision making, p. 385-409. In C. Nightingale, T. Murakawa, and P. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, New York, NY.
2. Baquero, F., and M. Negri. 1997. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays 19:731-736. (Pubitemid 27354094)
3. Baquero, F., M. Negri, M. Morosini, and J. Blazquez. 1997. The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Ciba Found. Symp. 207:93-105.
4. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. CLSI publication M07-A8, vol. 29, no. 2. CLSI, Wayne, PA.
5. Craig, W. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
6. Cui, J., et al. 2006. The mutant selection window demonstrated in rabbits infected with Staphylococcus aureus. J. Infect. Dis. 194:1601-1608.
7. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758.
8. Drlica, K., X. Zhao, J. Blondeau, and C. Hesje. 2006. Low correlation between minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC). Antimicrob. Agents Chemother. 50:403-404. (Pubitemid 43042960)
9. Jumbe, N., et al. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
10. Kornblum, J. S. 1987. Some findings concerning methicillin resistance in S. aureus and analysis of countertranscript RNAs of several pT181 copy mutants. Ph.D. dissertation. New York University, New York, NY.
11. Linde, H.-J., and N. Lehn. 2004. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J. Antimicrob. Chemother. 53:252-257.
12. Liu, Y., et al. 2005. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J. Antimicrob. Chemother. 56:1172-1175.
13. Marcusson, L., S. Olofsson, P. Lindgren, O. Cars, and D. Hughes. 2005. Mutant prevention concentration of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J. Antimicrob. Chemother. 55:938-943.
14. Olofsson, S., L. Marcusson, P. Komp-Lindgren, D. Hughes, and O. Cars. 2006. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 57:1116-1121.
15. Preston, S., et al. 1998. Pharmacodyamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129. (Pubitemid 28068302)
16. Randall, L., S. Cooles, L. Piddock, and M. Woodward. 2004. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. J. Antimicrob. Chemother. 54:688-691.
17. Schentag, J., A. Meagher, and A. Forest. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates part 2: human trials. Ann. Pharmacother. 37:1478-1488.
18. Schentag, J., A. Meagher, and A. Forrest. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann. Pharmacother. 37:1287-1298.
19. Stratton, C. 2003. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg. Infect. Dis. 9:10-16.
20. Tam, V., A. Louie, M. Deziel, W. Liu, and G. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51:744-747.
21. Tam, V., et al. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.
22. Viera, A. J., and J. M. Garrett. 2005. Understanding interobserver agreement: the kappa statistic. Fam. Med. 37:360-363.
23. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
24. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. J. Infect. Dis. 185:561-565.
25. Zhao, X., and K. Drlica. 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. 62:434-436.
26. Zhao, X., W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica. 2003. Mutant prevention concentration for garenoxacin (BMS-284756) with ciprofloxacin- susceptible and ciprofloxacin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1023-1027.